News14/Ratings0
Latest news
14 items- SECSEC Form 424B3 filed424B3 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form 10-Q filed10-Q - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form 424B4 filed424B4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form EFFECT filedEFFECT - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form SC 13G/A filedSC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECSEC Form S-1/A filedS-1/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form SC 13G/A filedSC 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECSEC Form S filedS-1 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form 4 filed4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
- SECSEC Form 4 filed4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
- SECSEC Form S filedSC 13D - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- PRReviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW NEW YORK and CUPERTINO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (“Reviva Holdings”), as the successor to Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”), a California-based clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced the compl
- PRTenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce Shareholder Meeting Date to Approve the Business CombinationNEW YORK and CUPERTINO, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that an Extraordinary General Meeting of Shareholders of Tenzing (the "Shareholder Meeting") to approve the pending business combination between Tenzing and Reviva (the “Business Combination”) is s
- PRTenzing Acquisition Corp. and Reviva Pharmaceuticals, Inc. Announce the Appointment of Narayan Prabhu as Chief Financial OfficerNEW YORK and CUPERTINO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical-stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Narayan Prabhu will join the combined public company as Chief Financial Officer following the completion of Tenzing’s proposed business combination with Reviva (the “Business Combination”). Mr